Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Viret Jean-Frederic | Chief Financial Officer | Jan 25 | Option Exercise | 10.05 | 40,000 | 402,000 | 107,439 | Jan 27 04:15 PM | Viret Jean-Frederic | Chief Financial Officer | Jan 25 | Sale | 19.95 | 46,144 | 920,736 | 61,295 | Jan 27 04:15 PM | Anicetti Vincent R | Chief Operating Officer | Jan 19 | Option Exercise | 2.50 | 2,500 | 6,251 | 62,239 | Jan 21 04:22 PM | Anicetti Vincent R | Chief Operating Officer | Jan 19 | Sale | 17.94 | 2,500 | 44,852 | 59,739 | Jan 21 04:22 PM | Anicetti Vincent R | Chief Operating Officer | Dec 17 | Option Exercise | 2.50 | 2,500 | 6,251 | 35,069 | Dec 21 04:10 PM | Anicetti Vincent R | Chief Operating Officer | Dec 17 | Sale | 17.51 | 2,500 | 43,780 | 32,569 | Dec 21 04:10 PM | Vexler Vladimir | Chief Scientific Officer | Dec 10 | Option Exercise | 2.08 | 17,626 | 36,729 | 54,299 | Dec 11 04:39 PM | Vexler Vladimir | Chief Scientific Officer | Dec 10 | Sale | 18.05 | 17,626 | 318,066 | 36,673 | Dec 11 04:39 PM | Vexler Vladimir | Chief Scientific Officer | Dec 09 | Option Exercise | 2.08 | 30,000 | 62,514 | 86,185 | Dec 11 04:39 PM | Vexler Vladimir | Chief Scientific Officer | Dec 09 | Sale | 18.24 | 49,512 | 903,084 | 36,673 | Dec 11 04:39 PM | Anicetti Vincent R | Chief Operating Officer | Dec 07 | Option Exercise | 12.59 | 8,791 | 110,656 | 41,360 | Dec 09 05:53 PM | Anicetti Vincent R | Chief Operating Officer | Dec 07 | Sale | 18.42 | 8,791 | 161,896 | 32,569 | Dec 09 05:53 PM | Anicetti Vincent R | Chief Operating Officer | Dec 04 | Option Exercise | 15.37 | 49,000 | 753,079 | 81,569 | Dec 07 04:51 PM | Anicetti Vincent R | Chief Operating Officer | Dec 04 | Sale | 18.85 | 49,000 | 923,694 | 32,569 | Dec 07 04:51 PM | Anicetti Vincent R | Chief Operating Officer | Dec 03 | Option Exercise | 17.32 | 49,756 | 861,602 | 82,325 | Dec 07 04:51 PM | Anicetti Vincent R | Chief Operating Officer | Dec 03 | Sale | 18.67 | 49,756 | 929,079 | 32,569 | Dec 07 04:51 PM | Anicetti Vincent R | Chief Operating Officer | Nov 18 | Option Exercise | 12.70 | 4,283 | 54,394 | 36,852 | Nov 19 04:16 PM | Anicetti Vincent R | Chief Operating Officer | Nov 18 | Sale | 18.00 | 4,283 | 77,094 | 32,569 | Nov 19 04:16 PM | Viret Jean-Frederic | Chief Financial Officer | Nov 17 | Option Exercise | 13.50 | 1,500 | 20,250 | 40,269 | Nov 19 04:16 PM | Anicetti Vincent R | Chief Operating Officer | Nov 17 | Option Exercise | 2.50 | 2,500 | 6,251 | 51,056 | Nov 19 04:16 PM | Viret Jean-Frederic | Chief Financial Officer | Nov 17 | Sale | 17.49 | 1,995 | 34,896 | 38,769 | Nov 19 04:16 PM | Anicetti Vincent R | Chief Operating Officer | Nov 17 | Sale | 17.66 | 18,487 | 326,416 | 32,569 | Nov 19 04:16 PM | Anicetti Vincent R | Chief Operating Officer | Oct 19 | Option Exercise | 4.77 | 3,217 | 15,357 | 51,773 | Oct 21 04:04 PM | Anicetti Vincent R | Chief Operating Officer | Oct 19 | Sale | 17.89 | 3,217 | 57,556 | 48,556 | Oct 21 04:04 PM | Viret Jean-Frederic | Chief Financial Officer | Oct 14 | Sale | 19.00 | 6,144 | 116,736 | 40,423 | Oct 16 04:19 PM | Anicetti Vincent R | Chief Operating Officer | Sep 17 | Option Exercise | 7.60 | 5,000 | 38,001 | 53,556 | Sep 21 05:06 PM | Anicetti Vincent R | Chief Operating Officer | Sep 17 | Sale | 18.84 | 5,000 | 94,216 | 48,556 | Sep 21 05:06 PM | Anicetti Vincent R | Chief Operating Officer | Aug 17 | Option Exercise | 7.60 | 5,000 | 38,001 | 53,556 | Aug 19 04:23 PM | Anicetti Vincent R | Chief Operating Officer | Aug 17 | Sale | 19.37 | 5,000 | 96,851 | 48,556 | Aug 19 04:23 PM | Anicetti Vincent R | Chief Operating Officer | Jul 17 | Option Exercise | 11.00 | 15,000 | 165,001 | 63,556 | Jul 21 05:04 PM | Anicetti Vincent R | Chief Operating Officer | Jul 17 | Sale | 18.25 | 15,000 | 273,687 | 48,556 | Jul 21 05:04 PM | Lanfear Dennis M | President & CEO | Jul 01 | Option Exercise | 0.01 | 29,994 | 249 | 193,258 | Jul 06 05:58 PM | Szela Mary T | Director | Jun 22 | Option Exercise | 8.84 | 54,997 | 485,900 | 54,997 | Jun 24 04:55 PM | Szela Mary T | Director | Jun 22 | Sale | 17.58 | 54,997 | 966,759 | 0 | Jun 24 04:55 PM | Anicetti Vincent R | Chief Operating Officer | Jun 17 | Option Exercise | 2.50 | 2,500 | 6,251 | 51,056 | Jun 19 04:35 PM | Anicetti Vincent R | Chief Operating Officer | Jun 17 | Sale | 17.22 | 2,500 | 43,050 | 48,556 | Jun 19 04:35 PM | Wahlstrom Mats | Director | Jun 17 | Sale | 17.15 | 200,000 | 3,430,020 | 0 | Jun 19 04:33 PM | Viret Jean-Frederic | Chief Financial Officer | May 20 | Sale | 17.66 | 1,278 | 22,569 | 46,567 | May 22 04:30 PM | Anicetti Vincent R | Chief Operating Officer | May 18 | Option Exercise | 2.50 | 2,500 | 6,251 | 51,056 | May 20 05:01 PM | Anicetti Vincent R | Chief Operating Officer | May 18 | Sale | 17.17 | 3,093 | 53,107 | 48,556 | May 20 05:01 PM | Anicetti Vincent R | Chief Operating Officer | Apr 20 | Sale | 17.00 | 5,150 | 87,550 | 47,846 | Apr 21 04:24 PM | Anicetti Vincent R | Chief Operating Officer | Apr 17 | Option Exercise | 2.50 | 5,000 | 12,503 | 57,996 | Apr 21 04:24 PM | Anicetti Vincent R | Chief Operating Officer | Apr 17 | Sale | 15.57 | 5,000 | 77,850 | 52,996 | Apr 21 04:24 PM | Wahlstrom Mats | Director | Mar 03 | Sale | 20.12 | 118,066 | 2,375,409 | 200,000 | Mar 05 04:31 PM | Viret Jean-Frederic | Chief Financial Officer | Feb 19 | Option Exercise | 10.05 | 3,159 | 31,748 | 50,000 | Feb 21 06:16 PM | Viret Jean-Frederic | Chief Financial Officer | Feb 19 | Sale | 22.33 | 3,159 | 70,552 | 46,841 | Feb 21 06:16 PM | Anicetti Vincent R | Chief Operating Officer | Feb 18 | Option Exercise | 7.60 | 5,000 | 38,001 | 60,496 | Feb 20 04:07 PM | Anicetti Vincent R | Chief Operating Officer | Feb 18 | Sale | 21.64 | 10,000 | 216,390 | 52,996 | Feb 20 04:07 PM |
|